CD137, also known as TNFRSF9 or 4-1BB, is an inducible costimulatory molecule expressed mainly on activated T cells. Its ligand, known as 4-1BBL, is expressed on activated macrophages, mature B cells, hematopoietic stem cells, and myeloid progenitor cells.

The 3H3 monoclonal antibody reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. 4-1BB is a 39 kDa transmembrane protein expressed by T lymphocytes, NK cells, dendritic cells, granulocytes, and mast cells. Upon binding its ligand 4-1BBL, 4-1BB provides costimulatory signals to both CD4 and CD8 T cells through the activation of NF-κB, c-Jun and p38 downstream pathways.

Cited in 2 publication(s). Independently reviewed in 1 review(s). Immunogen corresponding to fusion protein. CD137, also known as 4-1BB, is a member of the TNFR super family. CD137 is closely related to CD27, OX40, and CD30. It is up-regulated on mouse and human T cells upon activation. 2 It has long been recognized as a costimulatory molecule for T cells.

CD137, also known as TNFRSF9 or 4-1BB, is an inducible costimulatory molecule expressed mainly on activated T cells. Its ligand, known as 4-1BBL, is expressed on activated macrophages, mature B cells, hematopoietic stem cells, and myeloid progenitor cells. 2019-11-08 2020-10-20 CD137 is a 39 kD transmembrane protein also known as 4-1BB. It is expressed on activated T cells.

CD137 is a 39 kD transmembrane protein also known as 4-1BB. It is expressed on activated T cells. CD137 is a type I membrane protein and a member of the tumor necrosis factor receptor superfamily.

Cited in 4 publications. View Human 4-1BB/TNFRSF9/CD137 Antibody (AF838) validated in Human.

AU - Johansson Lindbom, Bengt. AU - Borrebaeck, Carl.

TNFRSF9 / 4-1BB / CD137 is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses.

2 It has long been recognized as a costimulatory molecule for T cells.

Anti-CD137 mAb is currently undergoing phase I and II clinical trials for cancer [28].
Skrivande i yrkeslivet

Fri frakt. Pris: 205,6 €. e-bok, 2015. Laddas ned direkt.

Several agonistic anti‐CD137 antibodies are currently in clinical trials for tumor immunotherapy. Soluble forms of CD137 (sCD137) are generated by differential splicing and antagonize the activities of membrane‐bound CD137 (mCD137) and of therapeutic CD137 agonists. sCD137 is found in sera of patients suffering from autoimmune diseases where it is 4-1BB/TNFRSF9/CD137: Products.
Teletekniker lediga jobb

CD137 Antibody (BBK-2) is a monoclonal anti-CD137 antibody that detects human CD137 by WB, IP, IF and FCM.

investigated the effects of CD137 signalling, demonstrating that binding of the CD137 ligand to its receptor increases proliferation and migration of smooth muscle cells. In summary, this thesis has focused on the expression, regulation and role of CXCL16 and CD137, two genes that have not been described earlier in the concept of atherosclerosis. CD137-transfected L-428 cells (L-428-CD137) were treated with 10 μg/ml of Fabs, followed by anti-Fab-AF647. All Fabs bound efficiently to CD137 + cells ( Supplementary Figure 3 ). No binding was observed to CD137 − L-428-control cells (not shown). 137A and 137C showed weaker binding affinity than the other Fabs, making them suitable for the generation of the bispecific antibody. CD137 Antibody (BBK-2) is a monoclonal anti-CD137 antibody that detects human CD137 by WB, IP, IF and FCM. CD137 (4-1BB, TNFRSF9) is increasingly recognized as a pow-erful inducer of antitumor immune responses.